Retatrutide + Tesamorelin Blend Australia | Metabolic Research Peptide Blend
The Retatrutide Tesamorelin blend combines two synthetic peptides widely referenced in scientific literature examining metabolic and growth hormone signalling pathways. As a metabolic research blend available in Australia, this Retatrutide Tesamorelin blend is cited across preclinical models investigating incretin receptor and growth hormone-releasing activity.
This blend is supplied as a combined 10mg Retatrutide + 10mg Tesamorelin vial (20mg total) as a lyophilised powder with third-party verification.
What Is Retatrutide + Tesamorelin?
This blend pairs two peptides studied in metabolic research. Retatrutide is a synthetic triple receptor agonist, referenced in literature examining GLP-1, GIP and glucagon receptor pathways. Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), referenced in research into growth hormone release and lipid-metabolism pathways. Together they are studied as a combined subject in preclinical models exploring metabolic and growth hormone signalling.
Retatrutide + Tesamorelin Specifications
Blend: Retatrutide + Tesamorelin
Strength: 10mg Retatrutide + 10mg Tesamorelin (20mg total)
Form: Lyophilised powder
Purity: 99%+
Verification: COA provided & independently tested
Storage: 2–8°C
Quality & Testing
Every batch supplied by Pureform Labs is independently analysed by a third-party laboratory for identity and purity. A Certificate of Analysis (COA) is available for each product so researchers can verify what they receive. View current lab results on our Lab Results page.
Ordering Retatrutide + Tesamorelin in Australia
This blend is held in local Australian stock and dispatched same day on orders placed before cut-off, with tracked delivery nationwide. On arrival, store the powder at 2–8°C, away from light, to maintain stability.
Disclaimer: This product is intended strictly for laboratory research use only. It is not for human or animal consumption, and not for diagnostic or therapeutic use.
